Cantor Fitzgerald Estimates Immunovant FY2026 Earnings

Immunovant, Inc. (NASDAQ:IMVTFree Report) – Investment analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Immunovant in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the company will earn ($2.92) per share for the year. The consensus estimate for Immunovant’s current full-year earnings is ($2.75) per share.

Several other equities analysts have also recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $51.00 price target on shares of Immunovant in a report on Friday, November 8th. Wolfe Research cut Immunovant from an “outperform” rating to a “peer perform” rating in a report on Friday, January 3rd. Raymond James reiterated an “outperform” rating and issued a $36.00 price target on shares of Immunovant in a report on Thursday, October 10th. Bank of America decreased their price target on Immunovant from $48.00 to $45.00 and set a “buy” rating on the stock in a report on Wednesday, January 15th. Finally, Oppenheimer increased their target price on Immunovant from $47.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Check Out Our Latest Stock Report on IMVT

Immunovant Stock Up 0.7 %

Immunovant stock opened at $23.40 on Thursday. The business’s 50-day simple moving average is $26.02 and its 200 day simple moving average is $28.42. The stock has a market cap of $3.43 billion, a price-to-earnings ratio of -10.54 and a beta of 0.66. Immunovant has a 12-month low of $22.41 and a 12-month high of $40.12.

Immunovant (NASDAQ:IMVTGet Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). During the same period in the prior year, the company posted ($0.45) earnings per share.

Insider Activity

In other news, CFO Eva Renee Barnett sold 2,298 shares of Immunovant stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $23.83, for a total transaction of $54,761.34. Following the transaction, the chief financial officer now owns 324,766 shares in the company, valued at $7,739,173.78. The trade was a 0.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mark S. Levine sold 3,650 shares of Immunovant stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $25.45, for a total value of $92,892.50. Following the transaction, the insider now owns 319,228 shares in the company, valued at $8,124,352.60. This trade represents a 1.13 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 68,040 shares of company stock worth $1,697,399 in the last 90 days. Corporate insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Immunovant

Several institutional investors have recently bought and sold shares of IMVT. Canada Pension Plan Investment Board bought a new stake in Immunovant in the 2nd quarter valued at approximately $5,275,000. Ensign Peak Advisors Inc lifted its stake in Immunovant by 22.2% in the 2nd quarter. Ensign Peak Advisors Inc now owns 204,221 shares of the company’s stock valued at $5,391,000 after acquiring an additional 37,165 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Immunovant by 5.6% in the 2nd quarter. Squarepoint Ops LLC now owns 49,288 shares of the company’s stock valued at $1,301,000 after acquiring an additional 2,615 shares in the last quarter. Armistice Capital LLC lifted its stake in Immunovant by 57.0% in the 2nd quarter. Armistice Capital LLC now owns 3,396,909 shares of the company’s stock valued at $89,678,000 after acquiring an additional 1,232,909 shares in the last quarter. Finally, Scientech Research LLC bought a new stake in Immunovant in the 2nd quarter valued at approximately $334,000. Institutional investors own 47.08% of the company’s stock.

Immunovant Company Profile

(Get Free Report)

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.

See Also

Earnings History and Estimates for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.